1. Finland Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Nexstim PLC

Nexstim PLC

8.60
EUR
-0.27
(-3.04%)
69.18MMarket Cap
Mar 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
38.7
49
34.51
20.29
3.25
16.53
9.49
1.2
1.05
1.46
1.09
1.27
1.53
- -
Basic EPS, GAAP
-93.39
-231.53
-134.15
-55.03
-9.01
-38.07
-19.23
-1.21
-0.14
0.2
-0.2
-0.13
0.08
- -
Free Cash Flow per Basic Share
-87.34
-191.62
-136.36
-61.59
-6.82
-42.08
-21.34
-1.1
-0.61
-0.07
-0.57
0.03
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-49.27
117.66
43.23
9.33
5.79
-0.29
-0.23
-0.26
0.48
0.61
0.42
0.52
0.58
1.17
Tangible Book Value per Share
-58.19
110.45
35.54
7.97
5.22
-0.72
-0.35
-0.32
0.31
0.29
-0.01
-0.01
-0.03
0.53
Basic Weighted Avg Shares
- -
- -
- -
- -
1
- -
- -
3
6
7
7
7
7
7
Sales/Revenue/Turnover
2
2
3
2
3
3
3
4
6
10
7
9
11
- -
Operating Margin (%)
-237.02
-352.85
-410.21
-269.72
-211.39
-236.35
-194.66
-81.01
-22.7
8.82
-16.47
-6.13
5.8
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
1
1
1
- -
Net Income, GAAP
-5
-10
-10
-7
-7
-6
-7
-4
-1
1
-1
-1
1
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.35
- -
- -
0.76
- -
Profit Margin (%)
-241.31
-472.55
-388.75
-271.2
-277.01
-230.31
-202.58
-100.19
-13.01
13.72
-18.32
-10.21
5.23
- -
Working Capital
1
11
6
7
9
6
3
2
4
4
2
3
2
4
LT Debt
4
3
3
4
4
7
5
4
3
3
4
4
3
2
Total Equity
-2
9
4
4
6
- -
-1
-1
3
4
3
4
4
8
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
11.44
- -
- -
7.27
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
18.6
- -
- -
8.67
- -
Return on Common Equity (%)
- -
- -
-161.96
-167.82
-146.57
- -
- -
- -
- -
35.94
-38.45
-27.3
14.54
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1
2
1
LT Borrowings
4
3
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
98
102
69

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
7
7
9
Cash, Cash Equivalents & STI
3
3
6
Accounts Receivable, Net
2
4
2
Inventories
1
1
1
Total Current Liabilities
6
6
6
Payables & Accruals
- -
- -
- -
ST Debt
1
2
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-8.35%
-55.56%
13.03%
Free Cash Flow
37.49%
88.55%
-121.29%
Net Income, GAAP
-80.32%
-147.09%
-164.24%
Sales/Revenue/Turnover
18.05%
25.32%
25.57%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
9
2025
- -
- -
11
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.13
2025
- -
- -
0.08
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mikko Johannes Karvinen
Full Time Employees
40
Sector
Health technology
Industry
Medical specialties
Address
ElimAeenkatu 9 B Helsinki Finland 00510
IPO Date
Nov 14, 2014
Website
nexstim.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Nexstim Plc (NXTMH.HE), a Finnish medical technology company founded in 2000 and headquartered in Helsinki, develops and commercializes navigated transcranial magnetic stimulation (nTMS) systems with proprietary SmartFocus 3D navigation technology for precise, personalized brain stimulation; its core offerings span the Diagnostics Business, featuring the NBS System 5 (FDA-cleared and CE-marked for presurgical mapping of speech and motor cortices) and the forthcoming NBS 6 diagnostics system (commercial launch planned for 2025), and the Therapy Business, including the NBT system and NBS System 6 (FDA-cleared for major depressive disorder treatment in the US and CE-marked for major depression and chronic neuropathic pain in Europe); over 240 diagnostic systems and 107 therapy-capable systems are installed worldwide across research universities, hospitals, and clinics in the US, Europe, and other regions. Subsidiaries include Nexstim Inc. and Nexstim Investments LLC in the US, and Nexstim Germany GmbH. The company targets neurosurgery, neuromodulation, neuroscience research, and treatments for challenging brain disorders such as major depressive disorder, chronic neuropathic pain, and emerging indications like Alzheimer's disease. In late 2024, Nexstim signed a development and distributorship agreement with Brainlab AG, designating Brainlab as distributor for certain products focused on non-invasive brain mapping solutions while securing up to EUR 5.1 million in equity investment, including an initial EUR 1.1 million share subscription; this partnership supports 2025 sales targets and expands market reach to Brainlab's global hospital network. In January 2025, Nexstim initiated co-development of the SinaptiStim precision neuromodulation system with Sinaptica Therapeutics Inc. for Alzheimer's treatment, integrating NBS 6 hardware with EEG software and planning first investigational system delivery in March 2025 under a potential 10-year exclusive arrangement. Recent expansions include US clinic partnerships via Nexstim Investments LLC (e.g., with RapidRecovery TMS, Dr. Kuluva, and Dr. Nadkarni), a new stock option plan (2025H) for the Board, a change in Certified Advisor to Carnegie Investment Bank AB, and shipment of the first NBS 6 therapy systems; full-year 2024 net sales grew 20.5% to EUR 8.7 million, with Therapy Business up 41.8% and positive EBITDA of EUR 0.3 million.